GAS5 Gene Expression and IL-6 in Rheumatoid Arthritis

ConditionRA - Rheumatoid Arthritis

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorSohag University

About this trial

This study aims to investigate the expression of Growth Arrest-Specific 5 (GAS5) , a long non-coding RNA , in patients with Rheumatoid Arthritis compared with healthy individuals. The study will also assess the level of Interlukin-6 (IL-6) in the blood and explore the relationship between GAS5 expression and IL-6 levels in Rheumatoid Arthritis

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adult patients older than 18 years patients diagnosed with Rheumatoid Arthritis according to the 2010 American collage Rheumatology / European League against Rheumatism (ACR/EULAR) classification criteria

Disqualifiers

Patients who did not meet the previous inclusion criteria

Trial population

Adult patients diagnosed with Rheumatoid Arthritis according to 2010 ACR/EULAR classification criteria and healthy controls participants who meet the predefined eligibility criteria

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

50 Participants

are grouped into 2 trial groups

Group A: Rheumatoid Arthritis

Group B: Healthy Controls

Trial outcomes

Primary outcomes

GAS5 gene expression level

GAS5 long non-coding RNA expression level in preipheral blood samples , assessed by quantitative real-time polymerase chain reaction (qRT-PCR) and compared between patients with rheumatoid arthritis and healthy controls

Time frame

at enrollment

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sohag University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: